Timing of Systemic or Catheter-Based Reperfusion in High and Intermediate-High Risk Acute Pulmonary Embolism

What this Trial Is About

Pulmonary embolism PE is a leading cause of death related to heart and blood vessel problems worldwide. This research aims to understand how the timing of treatments that clear blood clots, such as systemic thrombolysis or catheter-based therapies, affects survival and complications in patients with high-risk or intermediate-high-risk PE. The study seeks to find the best time window for these treatments to improve outcomes, as current guidelines do not specify exact timing. The study is a national, multicenter, prospective observational trial focusing on patients classified as high-risk or intermediate-high-risk PE according to European Society of Cardiology guidelines. It observes the use and timing of reperfusion treatments like systemic thrombolysis or catheter-directed therapies. These treatments are given as needed based on the patients condition, with no experimental drug or procedure assigned by the study. Participants will be monitored from enrollment through 30 days of treatment to track survival and any bleeding or heart-related complications. Data will be collected on treatment timing and patient outcomes without altering usual care. This approach helps researchers understand how timing influences the effectiveness and safety of reperfusion therapies in real-world settings.

Optimal Time for Reperfusion in Acute Pulmonary Embolism